DE3137125C2 - - Google Patents

Info

Publication number
DE3137125C2
DE3137125C2 DE3137125A DE3137125A DE3137125C2 DE 3137125 C2 DE3137125 C2 DE 3137125C2 DE 3137125 A DE3137125 A DE 3137125A DE 3137125 A DE3137125 A DE 3137125A DE 3137125 C2 DE3137125 C2 DE 3137125C2
Authority
DE
Germany
Prior art keywords
pah
administration
activity
pyridoxine
minutes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE3137125A
Other languages
German (de)
English (en)
Other versions
DE3137125A1 (de
Inventor
Francesco Mailand/Milano It Fici
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ISTITUTO LUSO FARMACO D'ITALIA SpA MAILAND/MILANO IT
Original Assignee
ISTITUTO LUSO FARMACO D'ITALIA SpA MAILAND/MILANO IT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ISTITUTO LUSO FARMACO D'ITALIA SpA MAILAND/MILANO IT filed Critical ISTITUTO LUSO FARMACO D'ITALIA SpA MAILAND/MILANO IT
Publication of DE3137125A1 publication Critical patent/DE3137125A1/de
Application granted granted Critical
Publication of DE3137125C2 publication Critical patent/DE3137125C2/de
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE19813137125 1980-09-22 1981-09-18 Verwendung von pyridoxin-(alpha)-ketoglutarat fuer die prophylaxe der hyperlactacidaemie Granted DE3137125A1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT24827/80A IT1141070B (it) 1980-09-22 1980-09-22 Impiego dell'alfa-chetoglutarato di piridossina nella profilassi della iperlattacidemia

Publications (2)

Publication Number Publication Date
DE3137125A1 DE3137125A1 (de) 1982-04-01
DE3137125C2 true DE3137125C2 ( ) 1989-04-06

Family

ID=11214855

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19813137125 Granted DE3137125A1 (de) 1980-09-22 1981-09-18 Verwendung von pyridoxin-(alpha)-ketoglutarat fuer die prophylaxe der hyperlactacidaemie

Country Status (12)

Country Link
US (1) US4361570A ( )
JP (1) JPS5782316A ( )
BE (1) BE890454A ( )
CA (1) CA1177408A ( )
CH (1) CH655009A5 ( )
DE (1) DE3137125A1 ( )
FR (1) FR2490493B1 ( )
GB (1) GB2084018A ( )
IT (1) IT1141070B ( )
NL (1) NL8104357A ( )
SE (1) SE459899B ( )
ZA (1) ZA816242B ( )

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6043259A (en) * 1998-07-09 2000-03-28 Medicure Inc. Treatment of cardiovascular and related pathologies
EP1169322B8 (en) 1999-03-08 2006-09-13 Medicure Inc. Pyridoxal analogues for the treatment of disorders caused by a deficiency in vitamin b6
EP1196171A2 (en) 1999-07-13 2002-04-17 Medicure Inc. Use of pyridoxin derivatives for the treatment of diabetes and related complications
EP1210117A2 (en) * 1999-08-24 2002-06-05 Medicure International Inc. Compositons for the treatment of cardiovascular diseases containing pyridoxal compounds and cardiovascular compounds
DE60133323T2 (de) 2000-02-29 2009-03-05 Medicure International Inc. Cardioprotektive Phosphonate
US7442689B2 (en) * 2000-02-29 2008-10-28 Medicure International Inc. Cardioprotective phosphonates and malonates
JP2003528146A (ja) 2000-03-28 2003-09-24 メディキュア インターナショナル インコーポレイテッド 脳血管疾患の治療
US6897228B2 (en) * 2000-07-07 2005-05-24 Medicure International Inc. Pyridoxine and pyridoxal analogues: new uses
ATE364595T1 (de) 2000-07-07 2007-07-15 Medicure Int Inc Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika
US6548519B1 (en) 2001-07-06 2003-04-15 Medicure International Inc. Pyridoxine and pyridoxal analogues: novel uses
US20040121988A1 (en) * 2001-03-28 2004-06-24 Medicure International Inc. Treatment of cerebrovascular disease
US20040186077A1 (en) * 2003-03-17 2004-09-23 Medicure International Inc. Novel heteroaryl phosphonates as cardioprotective agents
US20070060549A1 (en) * 2004-08-10 2007-03-15 Friesen Albert D Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders
EP1817288A4 (en) 2004-10-28 2009-08-26 Medicure Int Inc DUAL ANTIPLÄTTCHEN / ANTIKOAGULANS PYRIDOXINANALOGE
US7459468B2 (en) 2004-10-28 2008-12-02 Medicure International, Inc. Aryl sulfonic pyridoxines as antiplatelet agents
WO2009073944A1 (en) * 2007-12-12 2009-06-18 Iovate T. & P. Inc. USE OF PYRIDOXINE α-HYDROXYISOCAPROATE TO REDUCE METABOLIC ACIDOSIS AND AMMONIA ACCUMULATION
US20090156648A1 (en) * 2007-12-12 2009-06-18 Iovate T. & P. Inc. Preparations containing pyridoxine and alpha-hydroxyisocaproic acid (HICA)
US10278327B2 (en) 2014-05-09 2019-05-07 Shakespeare Company, Llc Trimmer head for use with line and blades
US20210369750A1 (en) * 2018-10-24 2021-12-02 Ponce De Leon Health Designated Activity Company Nicotinamide riboside compositions for healthspan extension

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6453M ( ) * 1967-06-13 1968-11-12
ES360566A1 (es) * 1968-11-22 1970-10-16 Made Labor Sa Un metodo de obtencion de alfa-cetoglutarato de piridoxina y sus derivados.
US3784553A (en) * 1972-01-17 1974-01-08 Made Labor Sa Pyridoxine alpha-ketoglutarate and its derivatives

Also Published As

Publication number Publication date
DE3137125A1 (de) 1982-04-01
FR2490493A1 (fr) 1982-03-26
SE8105561L (sv) 1982-03-23
ZA816242B (en) 1982-08-25
CA1177408A (en) 1984-11-06
JPS5782316A (en) 1982-05-22
IT8024827A0 (it) 1980-09-22
FR2490493B1 (fr) 1986-03-07
IT1141070B (it) 1986-10-01
CH655009A5 (it) 1986-03-27
NL8104357A (nl) 1982-04-16
SE459899B (sv) 1989-08-21
GB2084018A (en) 1982-04-07
BE890454A (fr) 1982-01-18
US4361570A (en) 1982-11-30

Similar Documents

Publication Publication Date Title
DE3137125C2 ( )
DE69822665T2 (de) Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14-dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
DE69533940T2 (de) Therapeutische zusammensetzungen von venösdilatoren und arterielldilatoren
DE69028542T2 (de) Felbamat zur Behandlung der Lennox-Gastaut syndrome
DE69219136T2 (de) Flüssiges nahrungsmittel, das 3-guanidinopropionsäure enthält
EP0185210B1 (de) Verwendung von Dipeptidderivaten für die Herstellung von Arzneimitteln zur Behandlung von an amyotropher Lateralsklerose Erkrankten
DE3883606T2 (de) Verwendung von Fluoxetin zur Behandlung des Diabetes.
DE2823174A1 (de) Arzneimittel fuer die prophylaktische behandlung postoperativer tiefer venenthrombose
DE60028957T2 (de) Pharmazeutische zusammensetzungen enthaltend tetrac sowie deren verwendungsverfahren
DE3119460A1 (de) Pharmazeutische zusammensetzung aus l-karnitin und/oder l-acylkarnitin und verwendung der zusammensetzung gegen diabetes mellitus bei jugendlichen
DE2513940A1 (de) Pharmazeutische zubereitung
DE68915269T2 (de) Polyvalentes entzündungshemmendes mittel.
DE2530862C2 (de) Verwendung von Uridin-5'-diphosphat zur Verhütung und Behandlung von Alkoholismus
DE3875107T2 (de) Verwendung von fructose-1,6-diphosphat zur behandlung von akuten alkoholvergiftungen und chronischem alkoholismus und verwandte pharmazeutische zusammensetzungen.
DE69525348T2 (de) Medikament gegen myotonische dystrophie
DE69910600T2 (de) Verwendung von metformin gegen die gewichtszunahme, die mit valproat und andere psychotropische arzneimittel verbunden ist
DE69930624T2 (de) Arzneimittel für hinterstrangataxie und zusammensetzung zur behandlung von hinterstrangataxie
EP1001756B1 (de) Synergistisch wirkende zusammensetzungen zur selektiven bekämpfung von tumorgewebe
DE2743704C2 (de) L- oder DL-Phenylglycine enthaltende Arzneimittel
DE2445801A1 (de) Arzneimittel zur behandlung von diabetischer ketoacidose
DE69115102T2 (de) Stabilisator für eine 4-ethyl-2-hydroxyimino-5-nitro-3-hexenamide enthaltende Zusammensetzung und Stabilisierungsverfahren.
DE60207824T2 (de) Cytidin-diphosphocholin gegen diabetische neuropathie
DE19815411A1 (de) Thermogenese stimulierend wirksame Arzneimittel
EP0018550B1 (de) Mittel zur Behandlung von Muskelerkrankungen
DE3115322A1 (de) Oral zu verabreichendes, pharmazeutisch bzw. diagnostisch oder als nahrungsmittelzusatz wirksames bzw. verwendbares mittel

Legal Events

Date Code Title Description
8110 Request for examination paragraph 44
8128 New person/name/address of the agent

Representative=s name: TUERK, D., DIPL.-CHEM. DR.RER.NAT. GILLE, C., DIPL

D2 Grant after examination
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee